Companion Diagnostics Market by Technology Type (Immunohistochemistry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), In Situ Hybridization and Others), by Indication (Oncology, Neurology and Others)- Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Companion Diagnostics Market

Industry:  Life Sciences & Healthcare | Publish Date: Jan 2021 | No of Pages:  300 | No. Tables:  163 | No. Figures:  133

Market Definition

The global Companion Diagnostics Market size was valued at USD 1.96 billion in 2019 and is predicted to reach USD 9.02 billion by 2030, with a CAGR of 14.8% from 2020-2030.

Companion Diagnostic (CDx) is a clinical test co-developed with a therapeutic drug for screening the responders and non-responders to that particular drug. It is done in order to identify a patient group that can or cannot be treated with that corresponding drug. CDx helps practitioners to determine the benefits, side effects, and risks associated with the intake of therapeutic drugs, thereby ensuring patient’s safety.

The increasing preferences for targeted therapies, growing applications of personalized medicines, higher prevalence of chronic diseases, and increasing incidences of allergies in patients due to side effects of medicines; give rise to development of customized CDx, thereby propagating the global companion diagnostics market growth.

Additionally, the benefits offered by CDx test such as cost-effectiveness, high sensitivity, fast and accurate results in less time frames; further escalate the growth of companion diagnostics market.

Market Dynamics and Trends

According to data provided by World Health Organization in 2018; 1 in 6 deaths are caused due to cancer every year. At the global level, an estimated 6.8 million people die every year suffering from neurological disorders. CDx holds wide application for indication, in chronic disorders such as oncology, neurology, and others. This scenario further supplements the growth of the global companion diagnostics market.

However, costly R&D procedures to develop new CDx, and unfavorable reimbursement policies, restrict the growth of global companion diagnostics industry.

Moreover, upsurge in R&D activities, and an increasing number of approvals granted by the U.S Food Drug Administration (FDA), are expected to propagate the growth of global companion diagnostics market in coming future.

 

Market Segmentations and Scope of the Study

The global companion diagnostics market share has been analyzed based on technology, type, indication, and geography.

Based on technology, the market is segmented into Immunohistochemistry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), In Situ Hybridization, and others. Based on indication, the market is divided into Oncology, Neurology, and others. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.

 

Geographical Analysis

North America is expected to dominate the global companion diagnostics market, throughout the forecast period, accounting for the highest market share. This is attributed to well-established healthcare infrastructures and medical laboratories, increased investments in R&D activities to develop advanced precision medicine, as well as growing preferences towards personalized medicinal therapies in this region.

Asia Pacific region is expected to grow substantially in the global companion diagnostics market, with the highest CAGR values, owing to improving healthcare facilities, increased geriatric population prone to cancer & neurological disorders, as well as increasing medical tourism in this region.

 

Competitive Landscape

The companion diagnostics industry is highly competitive and consists of various market players. Some of the major market players include Abbott Laboratories Molecular, Inc., ARUP Laboratories, Inc., Agilent (Dako Denmark A/S), Danaher Corporation (Leica Microsystems), BioMerieux SA, Foundation Medicine, Inc., Qiagen N.V., Myriad Genetics, Inc., Thermo Fisher Scientific (Life Technologies Corporation), and Roche (Ventana Medical Systems, Inc.) among others.

The key players are employing strategies such as joint ventures for co-developing new products, and acquisitions, in-order to gain stronger position in the companion diagnostics market.

For instance, in March 2020, Thermo Fisher Scientific, one of the major players of companion diagnostics market, announced the signing of an agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson, to co-develop a CDx for cancer. Thermo Fisher's Oncomine Dx Target Test contains 46 cancer-related biomarkers for detection of both DNA and RNA variants. Its workflow features fast turnaround time and lowest sample requirements as compared to conventional oncology tests.

In June 2020, Thermo Fisher Scientific, announced that it has extended its strategic partnership with Agios Pharmaceuticals, by signing an extended agreement to co-develop a global CDx for Low-Grade Glioma (LGG) in oncology. This CDx test includes the identification of IDH gene mutations using the Ion Torrent Genexus System and Oncomine Precision Assay test, for LGG patients.

Key Benefits

  • The companion diagnostics market report provides the quantitative analysis of the current market and estimations through 2020-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the companion diagnostics market trend including the current and future trends for depicting the prevalent investment pockets in the market.

  • The report provides detailed information related to key drivers, restraints, opportunities, and their impact on the companion diagnostics market is provided in the report.

  • The report incorporates competitive analysis of the market players along with their market share in the global companion diagnostics market.

  • The SWOT analysis and Porters Five Forces model is elaborated in the study companion diagnostics market.

  • Value chain analysis in the companion diagnostics market study provides a clear picture of the stakeholders’ roles.

Companion Diagnostics Market Key Segments

By Technology Type

  • Immunohistochemistry

  • Polymerase Chain Reaction (PCR)

  • Next Generation Sequencing (NGS)

  • In Situ Hybridization

  • Others

By Indication

  • Oncology

  • Neurology

  • Others 

By Geography

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia

    • Rest of Asia-Pacific

  • RoW

    • UAE

    • Saudi Arabia

    • South Africa

    • Brazil

    • Remaining countries

Report Scope and Segmentation

Parameters

Details

Analysis Period

2019–2030

Base Year Considered

2020

Forecast Period

2020–2030

Market Size Estimation

Billion (USD)

Market Segmentation

By Technology (Immunohistochemistry, Polymerase Chain Reaction (Pcr), Next Generation Sequencing (Ngs), In Situ Hybridization, Other Technology) By Indication (Oncology, Neurology, Other Indication)

Geographical Segmentation

North America (U.S., Canada, Mexico) Europe (UK, Germany, France, Rest of Europe), Asia-Pacific (China, Japan, Australia, Rest of APAC), Rest of the World (Brazil, South Africa, Remaining Countries)

Companies Profiled

Abbott Laboratories Molecular, Inc., ARUP Laboratories, Inc., Agilent (Dako Denmark A/S), Danaher Corporation (Leica Microsystems), BioMerieux SA, Foundation Medicine, Inc., Qiagen N.V., Myriad Genetics, Inc., Thermo Fisher Scientific (Life Technologies Corporation), and Roche (Ventana Medical Systems, Inc.)
column chart pie chart

Test

1. INTRODUCTION

1.1.           REPORT DESCRIPTION

1.2.           RESEARCH METHODOLOGY

1.2.1             SECONDARY RESEARCH

1.2.2             DATA ANALYSIS FRAMEWORK

1.2.3             MARKET SIZE ESTIMATION

1.2.4             FORECASTING

1.2.5             PRIMARY RESEARCH AND DATA VALIDATION

2. MARKET SNAPSHOT, 2022-2030 MILLION USD

2.1.           MARKET SNAPSHOT

3. PORTER’S FIVE FORCE MODEL ANALYSIS

4. MARKET DYNAMICS

4.1.           GROWTH DRIVERS

4.1.1             DRIVER 1

4.1.2             DRIVER 2

4.1.3             DRIVER 3

4.1.4             DRIVER 4

4.2.           CHALLENGES

4.2.1             CHALLENGE 1

4.2.2             CHALLENGE 2

4.3.           OPPORTUNITIES

4.3.1             OPPORTUNITY 1

4.3.2             OPPORTUNITY 2

5. GLOBAL  COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

5.1.           OVERVIEW

5.2.           IMMUNOHISTOCHEMISTRY

5.2.1             IMMUNOHISTOCHEMISTRY MARKET, BY REGION

5.2.1.1        NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY

5.2.1.2        EUROPE IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY

5.2.1.3        ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY

5.2.1.4        REST OF WORLD IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY

5.3.           POLYMERASE CHAIN REACTION (PCR)

5.3.1             POLYMERASE CHAIN REACTION (PCR) MARKET, BY REGION

5.3.1.1        NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET, BY COUNTRY

5.3.1.2        EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET, BY COUNTRY

5.3.1.3        ASIA-PACIFIC POLYMERASE CHAIN REACTION (PCR) MARKET, BY COUNTRY

5.3.1.4        REST OF WORLD POLYMERASE CHAIN REACTION (PCR) MARKET, BY COUNTRY

5.4.           NEXT GENERATION SEQUENCING (NGS)

5.4.1             NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION

5.4.1.1        NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY

5.4.1.2        EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY

5.4.1.3        ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY

5.4.1.4        REST OF WORLD NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY

5.5.           IN SITU HYBRIDIZATION

5.5.1             IN SITU HYBRIDIZATION MARKET, BY REGION

5.5.1.1        NORTH AMERICA IN SITU HYBRIDIZATION MARKET, BY COUNTRY

5.5.1.2        EUROPE IN SITU HYBRIDIZATION MARKET, BY COUNTRY

5.5.1.3        ASIA-PACIFIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY

5.5.1.4        REST OF WORLD IN SITU HYBRIDIZATION MARKET, BY COUNTRY

5.6.           OTHER TECHNOLOGY

5.6.1             OTHER TECHNOLOGY MARKET, BY REGION

5.6.1.1        NORTH AMERICA OTHER TECHNOLOGY MARKET, BY COUNTRY

5.6.1.2        EUROPE OTHER TECHNOLOGY MARKET, BY COUNTRY

5.6.1.3        ASIA-PACIFIC OTHER TECHNOLOGY MARKET, BY COUNTRY

5.6.1.4        REST OF WORLD OTHER TECHNOLOGY MARKET, BY COUNTRY

6. GLOBAL  COMPANION DIAGNOSTICS MARKET, BY INDICATION

6.1.           OVERVIEW

6.2.           ONCOLOGY

6.2.1             GLOBAL ONCOLOGY MARKET, BY INDICATION

6.2.1.1        LUNG CANCER MARKET, BY REGION

6.2.1.1.1        NORTH AMERICA LUNG CANCER MARKET, BY COUNTRY

6.2.1.1.2        EUROPE LUNG CANCER MARKET, BY COUNTRY

6.2.1.1.3        ASIA-PACIFIC LUNG CANCER MARKET, BY COUNTRY

6.2.1.1.4        REST OF WORLD LUNG CANCER MARKET, BY COUNTRY

6.2.1.2        COLORECTAL CANCER MARKET, BY REGION

6.2.1.2.1        NORTH AMERICA COLORECTAL CANCER MARKET, BY COUNTRY

6.2.1.2.2        EUROPE COLORECTAL CANCER MARKET, BY COUNTRY

6.2.1.2.3        ASIA-PACIFIC COLORECTAL CANCER MARKET, BY COUNTRY

6.2.1.2.4        REST OF WORLD COLORECTAL CANCER MARKET, BY COUNTRY

6.2.1.3        BREAST CANCER MARKET, BY REGION

6.2.1.3.1        NORTH AMERICA BREAST CANCER MARKET, BY COUNTRY

6.2.1.3.2        EUROPE BREAST CANCER MARKET, BY COUNTRY

6.2.1.3.3        ASIA-PACIFIC BREAST CANCER MARKET, BY COUNTRY

6.2.1.3.4        REST OF WORLD BREAST CANCER MARKET, BY COUNTRY

6.2.1.4        BLOOD CANCER MARKET, BY REGION

6.2.1.4.1        NORTH AMERICA BLOOD CANCER MARKET, BY COUNTRY

6.2.1.4.2        EUROPE BLOOD CANCER MARKET, BY COUNTRY

6.2.1.4.3        ASIA-PACIFIC BLOOD CANCER MARKET, BY COUNTRY

6.2.1.4.4        REST OF WORLD BLOOD CANCER MARKET, BY COUNTRY

6.2.1.5        OTHERS MARKET, BY REGION

6.2.1.5.1        NORTH AMERICA OTHERS MARKET, BY COUNTRY

6.2.1.5.2        EUROPE OTHERS MARKET, BY COUNTRY

6.2.1.5.3        ASIA-PACIFIC OTHERS MARKET, BY COUNTRY

6.2.1.5.4        REST OF WORLD OTHERS MARKET, BY COUNTRY

6.2.2             ONCOLOGY MARKET, BY REGION

6.2.2.1        NORTH AMERICA ONCOLOGY MARKET, BY COUNTRY

6.2.2.2        EUROPE ONCOLOGY MARKET, BY COUNTRY

6.2.2.3        ASIA-PACIFIC ONCOLOGY MARKET, BY COUNTRY

6.2.2.4        REST OF WORLD ONCOLOGY MARKET, BY COUNTRY

6.3.           NEUROLOGY

6.3.1             NEUROLOGY MARKET, BY REGION

6.3.1.1        NORTH AMERICA NEUROLOGY MARKET, BY COUNTRY

6.3.1.2        EUROPE NEUROLOGY MARKET, BY COUNTRY

6.3.1.3        ASIA-PACIFIC NEUROLOGY MARKET, BY COUNTRY

6.3.1.4        REST OF WORLD NEUROLOGY MARKET, BY COUNTRY

6.4.           OTHER INDICATION

6.4.1             OTHER INDICATION MARKET, BY REGION

6.4.1.1        NORTH AMERICA OTHER INDICATION MARKET, BY COUNTRY

6.4.1.2        EUROPE OTHER INDICATION MARKET, BY COUNTRY

6.4.1.3        ASIA-PACIFIC OTHER INDICATION MARKET, BY COUNTRY

6.4.1.4        REST OF WORLD OTHER INDICATION MARKET, BY COUNTRY

7. GLOBAL  COMPANION DIAGNOSTICS MARKET, BY REGION

7.1.           OVERVIEW

7.2.           NORTH AMERICA

7.2.1             NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.2.2             NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.2.2.1        NORTH AMERICA  ONCOLOGY MARKET, BY INDICATION

7.2.3             NORTH AMERICA COMPANION DIAGNOSTICS, MARKET BY COUNTRY

7.2.3.1        U.S.

7.2.3.1.1        U.S. COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.2.3.1.2        U.S. COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.2.3.1.2.1. U.S. ONCOLOGY MARKET, BY INDICATION

7.2.3.2        CANADA

7.2.3.2.1        CANADA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.2.3.2.2        CANADA COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.2.3.2.2.1. CANADA ONCOLOGY MARKET, BY INDICATION

7.2.3.3        MEXICO

7.2.3.3.1        MEXICO COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.2.3.3.2        MEXICO COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.2.3.3.2.1. MEXICO ONCOLOGY MARKET, BY INDICATION

7.3.           EUROPE

7.3.1             EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.3.2             EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.3.2.1        EUROPE  ONCOLOGY MARKET, BY INDICATION

7.3.3             EUROPE COMPANION DIAGNOSTICS, MARKET BY COUNTRY

7.3.3.1        GERMANY

7.3.3.1.1        GERMANY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.3.3.1.2        GERMANY COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.3.3.1.2.1. GERMANY ONCOLOGY MARKET, BY INDICATION

7.3.3.2        UK

7.3.3.2.1        UK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.3.3.2.2        UK COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.3.3.2.2.1. UK ONCOLOGY MARKET, BY INDICATION

7.3.3.3        FRANCE

7.3.3.3.1        FRANCE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.3.3.3.2        FRANCE COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.3.3.3.2.1. FRANCE ONCOLOGY MARKET, BY INDICATION

7.3.3.4        REST OF EUROPE

7.3.3.4.1        REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.3.3.4.2        REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.3.3.4.2.1. REST OF EUROPE ONCOLOGY MARKET, BY INDICATION

7.4.           ASIA-PACIFIC

7.4.1             ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.4.2             ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.4.2.1        ASIA-PACIFIC  ONCOLOGY MARKET, BY INDICATION

7.4.3             ASIA-PACIFIC COMPANION DIAGNOSTICS, MARKET BY COUNTRY

7.4.3.1        AUSTRALIA

7.4.3.1.1        AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.4.3.1.2        AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.4.3.1.2.1. AUSTRALIA ONCOLOGY MARKET, BY INDICATION

7.4.3.2        JAPAN

7.4.3.2.1        JAPAN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.4.3.2.2        JAPAN COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.4.3.2.2.1. JAPAN ONCOLOGY MARKET, BY INDICATION

7.4.3.3        CHINA

7.4.3.3.1        CHINA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.4.3.3.2        CHINA COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.4.3.3.2.1. CHINA ONCOLOGY MARKET, BY INDICATION

7.4.3.4        REST OF ASIA-PACIFIC

7.4.3.4.1        REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.4.3.4.2        REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.4.3.4.2.1. REST OF ASIA-PACIFIC ONCOLOGY MARKET, BY INDICATION

7.5.           REST OF WORLD

7.5.1             REST OF WORLD COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.5.2             REST OF WORLD COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.5.2.1        REST OF WORLD  ONCOLOGY MARKET, BY INDICATION

7.5.3             REST OF WORLD COMPANION DIAGNOSTICS, MARKET BY COUNTRY

7.5.3.1        BRAZIL

7.5.3.1.1        BRAZIL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.5.3.1.2        BRAZIL COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.5.3.1.2.1. BRAZIL ONCOLOGY MARKET, BY INDICATION

7.5.3.2        SOUTH AFRICA

7.5.3.2.1        SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.5.3.2.2        SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.5.3.2.2.1. SOUTH AFRICA ONCOLOGY MARKET, BY INDICATION

7.5.3.3        REMAINING COUNTRIES

7.5.3.3.1        REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.5.3.3.2        REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET, BY INDICATION

7.5.3.3.2.1. REMAINING COUNTRIES ONCOLOGY MARKET, BY INDICATION

8. COMPANY PROFILES

8.1.           ABBOTT LABORATORIES MOLECULAR, INC.

8.1.1             COMPANY OVERVIEW

8.1.2             COMPANY SNAPSHOT

8.1.3             OPERATING BUSINESS SEGMENTS

8.1.4             PRODUCT PORTFOLIO

8.1.5             BUSINESS PERFORMANCE

8.1.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.2.           AGILENT

8.2.1             COMPANY OVERVIEW

8.2.2             COMPANY SNAPSHOT

8.2.3             OPERATING BUSINESS SEGMENTS

8.2.4             PRODUCT PORTFOLIO

8.2.5             BUSINESS PERFORMANCE

8.2.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.3.           ARUP LABORATORIES, INC.

8.3.1             COMPANY OVERVIEW

8.3.2             COMPANY SNAPSHOT

8.3.3             OPERATING BUSINESS SEGMENTS

8.3.4             PRODUCT PORTFOLIO

8.3.5             BUSINESS PERFORMANCE

8.3.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.4.           BIOMERIEUX

8.4.1             COMPANY OVERVIEW

8.4.2             COMPANY SNAPSHOT

8.4.3             OPERATING BUSINESS SEGMENTS

8.4.4             PRODUCT PORTFOLIO

8.4.5             BUSINESS PERFORMANCE

8.4.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.5.           DANAHER CORPORATION

8.5.1             COMPANY OVERVIEW

8.5.2             COMPANY SNAPSHOT

8.5.3             OPERATING BUSINESS SEGMENTS

8.5.4             PRODUCT PORTFOLIO

8.5.5             BUSINESS PERFORMANCE

8.5.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.6.           FOUNDATION MEDICINE, INC.

8.6.1             COMPANY OVERVIEW

8.6.2             COMPANY SNAPSHOT

8.6.3             OPERATING BUSINESS SEGMENTS

8.6.4             PRODUCT PORTFOLIO

8.6.5             BUSINESS PERFORMANCE

8.6.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.7.           MYRIAD GENETICS, INC.

8.7.1             COMPANY OVERVIEW

8.7.2             COMPANY SNAPSHOT

8.7.3             OPERATING BUSINESS SEGMENTS

8.7.4             PRODUCT PORTFOLIO

8.7.5             BUSINESS PERFORMANCE

8.7.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.8.           ROCHE

8.8.1             COMPANY OVERVIEW

8.8.2             COMPANY SNAPSHOT

8.8.3             OPERATING BUSINESS SEGMENTS

8.8.4             PRODUCT PORTFOLIO

8.8.5             BUSINESS PERFORMANCE

8.8.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.9.           THERMO FISHER SCIENTIFIC

8.9.1             COMPANY OVERVIEW

8.9.2             COMPANY SNAPSHOT

8.9.3             OPERATING BUSINESS SEGMENTS

8.9.4             PRODUCT PORTFOLIO

8.9.5             BUSINESS PERFORMANCE

8.9.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.10.         QIAGEN N.V.

8.10.1           COMPANY OVERVIEW

8.10.2           COMPANY SNAPSHOT

8.10.3           OPERATING BUSINESS SEGMENTS

8.10.4           PRODUCT PORTFOLIO

8.10.5           BUSINESS PERFORMANCE

8.10.6           KEY STRATEGIC MOVES AND DEVELOPMENT

LIST OF TABLES

TABLE 1. GLOBAL  COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 2. IMMUNOHISTOCHEMISTRY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 3. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 4. EUROPE IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 5. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 6. REST OF WORLD IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 7. POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 8. NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 9. EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 10. ASIA-PACIFIC POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 11. REST OF WORLD POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 12. NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 13. NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 14. EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 15. ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 16. REST OF WORLD NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 17. IN SITU HYBRIDIZATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 18. NORTH AMERICA IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 19. EUROPE IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 20. ASIA-PACIFIC IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 21. REST OF WORLD IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 22. OTHER TECHNOLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 23. NORTH AMERICA OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 24. EUROPE OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 25. ASIA-PACIFIC OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 26. REST OF WORLD OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 27. GLOBAL  COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 28. GLOBAL ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 29. LUNG CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 30. NORTH AMERICA LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 31. EUROPE LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 32. ASIA-PACIFIC LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 33. REST OF WORLD LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 34. COLORECTAL CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 35. NORTH AMERICA COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 36. EUROPE COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 37. ASIA-PACIFIC COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 38. REST OF WORLD COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 39. BREAST CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 40. NORTH AMERICA BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 41. EUROPE BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 42. ASIA-PACIFIC BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 43. REST OF WORLD BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 44. BLOOD CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 45. NORTH AMERICA BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 46. EUROPE BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 47. ASIA-PACIFIC BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 48. REST OF WORLD BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 49. OTHERS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 50. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 51. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 52. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 53. REST OF WORLD OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 54. ONCOLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 55. NORTH AMERICA ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 56. EUROPE ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 57. ASIA-PACIFIC ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 58. REST OF WORLD ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 59. NEUROLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 60. NORTH AMERICA NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 61. EUROPE NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 62. ASIA-PACIFIC NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 63. REST OF WORLD NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 64. OTHER INDICATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 65. NORTH AMERICA OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 66. EUROPE OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 67. ASIA-PACIFIC OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 68. REST OF WORLD OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 69. GLOBAL  COMPANION DIAGNOSTICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 70. NORTH AMERICA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 71. NORTH AMERICA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 72. NORTH AMERICA  ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 73. U.S. COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 74. U.S. COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 75. U.S. ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 76. CANADA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 77. CANADA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 78. CANADA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 79. MEXICO COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 80. MEXICO COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 81. MEXICO ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 82. EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 83. EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 84. EUROPE  ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 85. GERMANY COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 86. GERMANY COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 87. GERMANY ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 88. UK COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 89. UK COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 90. UK ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 91. FRANCE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 92. FRANCE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 93. FRANCE ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 94. REST OF EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 95. REST OF EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 96. REST OF EUROPE ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 97. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 98. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 99. ASIA-PACIFIC  ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 100. AUSTRALIA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 101. AUSTRALIA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 102. AUSTRALIA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 103. JAPAN COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 104. JAPAN COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 105. JAPAN ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 106. CHINA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 107. CHINA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 108. CHINA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 109. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 110. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 111. REST OF ASIA-PACIFIC ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 112. REST OF WORLD COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 113. REST OF WORLD COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 114. REST OF WORLD  ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 115. BRAZIL COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 116. BRAZIL COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 117. BRAZIL ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 118. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 119. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 120. SOUTH AFRICA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 121. REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

TABLE 122. REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 123. REMAINING COUNTRIES ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 124. ABBOTT LABORATORIES MOLECULAR, INC.: COMPANY SNAPSHOT

TABLE 125. ABBOTT LABORATORIES MOLECULAR, INC.: OPERATING SEGMENTS

TABLE 126. ABBOTT LABORATORIES MOLECULAR, INC.: PRODUCT PORTFOLIO

TABLE 127. ABBOTT LABORATORIES MOLECULAR, INC.: KEY STRATERGY

TABLE 128. AGILENT: COMPANY SNAPSHOT

TABLE 129. AGILENT: OPERATING SEGMENTS

TABLE 130. AGILENT: PRODUCT PORTFOLIO

TABLE 131. AGILENT: KEY STRATERGY

TABLE 132. ARUP LABORATORIES, INC.: COMPANY SNAPSHOT

TABLE 133. ARUP LABORATORIES, INC.: OPERATING SEGMENTS

TABLE 134. ARUP LABORATORIES, INC.: PRODUCT PORTFOLIO

TABLE 135. ARUP LABORATORIES, INC.: KEY STRATERGY

TABLE 136. BIOMERIEUX: COMPANY SNAPSHOT

TABLE 137. BIOMERIEUX: OPERATING SEGMENTS

TABLE 138. BIOMERIEUX: PRODUCT PORTFOLIO

TABLE 139. BIOMERIEUX: KEY STRATERGY

TABLE 140. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 141. DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 142. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 143. DANAHER CORPORATION: KEY STRATERGY

TABLE 144. FOUNDATION MEDICINE, INC.: COMPANY SNAPSHOT

TABLE 145. FOUNDATION MEDICINE, INC.: OPERATING SEGMENTS

TABLE 146. FOUNDATION MEDICINE, INC.: PRODUCT PORTFOLIO

TABLE 147. FOUNDATION MEDICINE, INC.: KEY STRATERGY

TABLE 148. MYRIAD GENETICS, INC.: COMPANY SNAPSHOT

TABLE 149. MYRIAD GENETICS, INC.: OPERATING SEGMENTS

TABLE 150. MYRIAD GENETICS, INC.: PRODUCT PORTFOLIO

TABLE 151. MYRIAD GENETICS, INC.: KEY STRATERGY

TABLE 152. ROCHE: COMPANY SNAPSHOT

TABLE 153. ROCHE: OPERATING SEGMENTS

TABLE 154. ROCHE: PRODUCT PORTFOLIO

TABLE 155. ROCHE: KEY STRATERGY

TABLE 156. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 157. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 158. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 159. THERMO FISHER SCIENTIFIC: KEY STRATERGY

TABLE 160. QIAGEN N.V.: COMPANY SNAPSHOT

TABLE 161. QIAGEN N.V.: OPERATING SEGMENTS

TABLE 162. QIAGEN N.V.: PRODUCT PORTFOLIO

TABLE 163. QIAGEN N.V.: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. GLOBAL  COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 2. IMMUNOHISTOCHEMISTRY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 3. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 4. EUROPE IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 5. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 6. REST OF WORLD IMMUNOHISTOCHEMISTRY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 7. POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 8. NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 9. EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 10. ASIA-PACIFIC POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 11. REST OF WORLD POLYMERASE CHAIN REACTION (PCR) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 12. NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 13. NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 14. EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 15. ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 16. REST OF WORLD NEXT GENERATION SEQUENCING (NGS) MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 17. IN SITU HYBRIDIZATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 18. NORTH AMERICA IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 19. EUROPE IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 20. ASIA-PACIFIC IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 21. REST OF WORLD IN SITU HYBRIDIZATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 22. OTHER TECHNOLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 23. NORTH AMERICA OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 24. EUROPE OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 25. ASIA-PACIFIC OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 26. REST OF WORLD OTHER TECHNOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 27. GLOBAL  COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 28. GLOBAL ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 29. LUNG CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 30. NORTH AMERICA LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 31. EUROPE LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 32. ASIA-PACIFIC LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 33. REST OF WORLD LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 34. COLORECTAL CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 35. NORTH AMERICA COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 36. EUROPE COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 37. ASIA-PACIFIC COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 38. REST OF WORLD COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 39. BREAST CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 40. NORTH AMERICA BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 41. EUROPE BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 42. ASIA-PACIFIC BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 43. REST OF WORLD BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 44. BLOOD CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 45. NORTH AMERICA BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 46. EUROPE BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 47. ASIA-PACIFIC BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 48. REST OF WORLD BLOOD CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 49. OTHERS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 50. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 51. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 52. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 53. REST OF WORLD OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 54. ONCOLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 55. NORTH AMERICA ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 56. EUROPE ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 57. ASIA-PACIFIC ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 58. REST OF WORLD ONCOLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 59. NEUROLOGY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 60. NORTH AMERICA NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 61. EUROPE NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 62. ASIA-PACIFIC NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 63. REST OF WORLD NEUROLOGY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 64. OTHER INDICATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 65. NORTH AMERICA OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 66. EUROPE OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 67. ASIA-PACIFIC OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 68. REST OF WORLD OTHER INDICATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 69. GLOBAL  COMPANION DIAGNOSTICS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 70. NORTH AMERICA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 71. NORTH AMERICA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 72. NORTH AMERICA  ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 73. U.S. COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 74. U.S. COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 75. U.S. ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 76. CANADA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 77. CANADA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 78. CANADA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 79. MEXICO COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 80. MEXICO COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 81. MEXICO ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 82. EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 83. EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 84. EUROPE  ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 85. GERMANY COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 86. GERMANY COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 87. GERMANY ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 88. UK COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 89. UK COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 90. UK ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 91. FRANCE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 92. FRANCE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 93. FRANCE ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 94. REST OF EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 95. REST OF EUROPE COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 96. REST OF EUROPE ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 97. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 98. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 99. ASIA-PACIFIC  ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 100. AUSTRALIA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 101. AUSTRALIA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 102. AUSTRALIA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 103. JAPAN COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 104. JAPAN COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 105. JAPAN ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 106. CHINA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 107. CHINA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 108. CHINA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 109. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 110. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 111. REST OF ASIA-PACIFIC ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 112. REST OF WORLD COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 113. REST OF WORLD COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 114. REST OF WORLD  ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 115. BRAZIL COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 116. BRAZIL COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 117. BRAZIL ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 118. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 119. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 120. SOUTH AFRICA ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 121. REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET VALUE, BY TECHNOLOGY, 2022-2030, MILLION USD

FIGURE 122. REMAINING COUNTRIES COMPANION DIAGNOSTICS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 123. REMAINING COUNTRIES ONCOLOGY MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 124. ABBOTT LABORATORIES MOLECULAR, INC.: NET SALES,2017-2019

FIGURE 125. AGILENT: NET SALES,2017-2019

FIGURE 126. ARUP LABORATORIES, INC.: NET SALES,2017-2019

FIGURE 127. BIOMERIEUX: NET SALES,2017-2019

FIGURE 128. DANAHER CORPORATION: NET SALES,2017-2019

FIGURE 129. FOUNDATION MEDICINE, INC.: NET SALES,2017-2019

FIGURE 130. MYRIAD GENETICS, INC.: NET SALES,2017-2019

FIGURE 131. ROCHE: NET SALES,2017-2019

FIGURE 132. THERMO FISHER SCIENTIFIC: NET SALES,2017-2019

FIGURE 133. QIAGEN N.V.: NET SALES,2017-2019

KEY PLAYERS:

  • Abbott Laboratories Molecular, Inc.
  • ARUP Laboratories, Inc.
  • Agilent (Dako Denmark A/S)
  • Danaher Corporation (Leica Microsystems)
  • BioMerieux SA
  • Foundation Medicine, Inc.
  • Qiagen N.V.
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific (Life Technologies Corporation)
  • Roche (Ventana Medical Systems, Inc.)

Frequently Asked Questions
What will be the worth of global Companion Diagnostics Market by the end of 2030?

According to the report published by Next Move Strategy Consulting, the Companion Diagnostics market business is expected to hit at $9.02 billion (USD) by 2030.

Which region is expected to hold the highest market share in the Companion Diagnostics Market?

North America is expected to hold the highest market share in the global market. The region is expected to witness remarkable growth as it houses the major key players in the market.

Which are the top companies in the Companion Diagnostics industry?

Abbott Laboratories Molecular, Inc., ARUP Laboratories, Inc., Agilent (Dako Denmark A/S), Danaher Corporation (Leica Microsystems), BioMerieux SA, Foundation Medicine, Inc., Qiagen N.V., Myriad Genetics, Inc., Thermo Fisher Scientific (Life Technologies Corporation), and Roche

What are the market segmentations and scope of the study?

The global Companion Diagnostics market share is analyzed on the basis of technology, type, indication, and geography.

How big is the Companion Diagnostics Market?

Currently (in 2019), the market value stands at USD 1.96 billion and it is anticipated to reach USD 9.02 billion by 2030.